Open Accessibility Menu

Sabyasachi Sen, MD

Need an Appointment ?
Contact (202) 741-3333
Sabyasachi Sen MD Sabyasachi Sen MD

Specialties

Titles

  • Associate Professor, Endocrinology | Associate Professor of Anatomy & Cellular Biology
Medical Biography
Clinical Interests
  • Primary lipid disorders Cardiovascular complications of Metabolic Syndrome
  • Prediabetes
  • Diabetes
  • Endocrine Hypertension
  • Medical School
    • Calcutta University, India
  • Residency
    • St Elizabeth's Medical Center, Boston. MA
  • Fellowship
    • Endocrinology, National Institutes of Health
Board Certified
  • Internal Medicine
  • Endocrinology
  • Diabetes and Metabolism

Sabyasachi Sen, MD, FACP, FACE is board-certified in Endocrinology and Internal Medicine.  He is also an associate professor The George Washington University School of Medicine & Health Sciences. Dr. Sen attended medical school at Calcutta University in India. Dr. Sen completed his Internal Medicine residency from Tufts University School of Medicine and a fellowship in endocrinology from the National Institutes of Health.   He undertook extensive training in Internal Medicine Endocrinology then completed his doctorate in Medicine from Britain and Ireland. Previously, he was an Endocrinology faculty member at Tufts University School of Medicine.

Dr. Sen’s basic research interest involves behavior (survival and differentiation) of human adult stem cells in hyperglycemia. His current research projects include: the effect of exercise and incretins on endothelial dysfunction and endothelial progenitor cells in patients with Prediabetes and early type 2 diabetes; use of apoptosis resistant endothelial progenitor cells to increase collateral vessel formation in diabetes with peripheral vascular disease; and use of genetically engineered mesenchymal stem cells to reduce inflammation and insulin resistance in diabetes. In 2012, he received the American Heart Association’s Scientific Development Grant and Investigator Initiated Study Grant from the Together on Diabetes Project, a scientific grant funding mechanism from Bristol Myers Squibb.

His research interests include: survival and differentiation of human adult stem cells in hyperglycemia, use of stem cells to treat diabetes complications such as NASH, CKD, MI and PVD, and use of adult stem cells to predict cardio-metabolic health in response to exercise, artificial sweeteners, food additives and diabetes medications.

Dr. Sen has won several awards for oral presentations at American Heart Association and The Endocrine Society. He is a member of the Royal College of Physicians, London; the American Heart Association, American Diabetes Association and the Endocrine Society, and is also a Fellow of the American College of Physicians and American College of Endocrinology.

  • External Grant Funded Projects

    • Use of P53 silenced Endothelial Progenitor Stem Cells to treat diabetic kidney disease—American Heart Association
    • Role of Linagliptin in improving renal failure by improving CD34+ stem cell number, function and gene expression in type 2 diabetes patients with impaired renal function—Investigator Initiated Study with Bohringer Ingelheim and ADA
    • Role of Canagliflozin on gene expression and function of CD34+ endothelial progenitor cells in patients with type 2 diabetes-- Investigator Initiated Study with Janssen and ADA
    • Use of CD34+ cell number, function and gene expression in evaluating endothelial dysfunction in patients with type 2 diabetes with CVD, pre and post dapagliflozin vs saxagliptin+dapagliflozin combination therapy -- Investigator Initiated Study with Astra-Zeneca and ADA
    • Effect of long acting GLP1 agonist Semaglutide on endothelium progenitor cell survival and fat differentiation in type 2 diabetes subjects with CVD-- Investigator Initiated Study with Novo-Nordisk and ADA
    • Effect on current HIV Regimens on Endothelial Dysfunction—DC-CFAR (NIAID funded).
  • Research Publications

    • The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Dore FJ, Domingues CC, Ahmadi N, Kundu N, Kropotova Y, Houston S, Rouphael C, Mammadova A, Witkin L, Khiyami A, Amdur RL, Sen S., Cardiovasc Diabetol. 2018 May 3;17(1):65. doi: 10.1186/s12933-018-0709-9.
    • The Correlation of Arterial Stiffness with Biophysical Parameters and Blood Biochemistry. Khiyami AM, Dore FJ, Mammadova A, Amdur RL, Sen S., Metab Syndr Relat Disord. 2017 May;15(4):178-182. doi: 10.1089/met.2016.0136. Epub 2017 Feb 22.
    • Use of p53-Silenced Endothelial Progenitor Cells to Treat Ischemia in Diabetic Peripheral Vascular Disease. Kundu N, Domingues CC, Chou C, Ahmadi N, Houston S, Jerry DJ, Sen S., J Am Heart Assoc. 2017 Apr 1;6(4). pii: e005146. doi: 10.1161/JAHA.116.005146.
    • Poly-ADP-ribose polymerase inhibition enhances ischemic and diabetic wound healing by promoting angiogenesis. Zhou X, Patel D, Sen S., Shanmugam V, Sidawy A, Mishra L, Nguyen BN. J Vasc Surg. 2017 Apr;65(4):1161-1169.
    • Genetic modification of human mesenchymal stem cells helps to reduce adiposity and improve glucose tolerance in an obese diabetic mouse model. Sen S., Domingues CC, Rouphael C, Chou C, Kim C, Yadava N. Stem Cell Res Ther. 2015 Dec 9;6:242. doi: 10.1186/s13287-015-0224-9.
    • A six-week home exercise program improves endothelial function and CD34+ circulating progenitor cells in patients with pre-diabetes. Sabyasachi Sen, Sarah Witkowski, Ann Lagoy, Ashequl M. Islam: J Endocrinol Metab.2015; 5 (1-2):163-171
  • Featured Oral Presentations

    • Nabanita Kundu, Cleyton Domingues, Brent Abel, Neeki Ahmadi, Jay Patel, Allison C. Sylvetsky, Monica Skarulis, Kristina Rother, Sabyasachi Sen.: Sucralose Promotes Metabolic Dysregulation and Inflammation at the Endocrine Society 100th Annual Meeting, 2017 (Selected for High Impact Press Coverage).
    • Cleyton C Domingues, Nabanita Kundu, Neeki Ahmadi, Yana Kropotova, Sabyasachi Sen: Modified Human Mesenchymal Stromal Cells (MSCs) Improve Glucose Homeostasis and fatty liver disease in Diet induced Obese (DIO) Diabetic Mouse Model, at the American Diabetes Association's 78th Scientific Sessions, June 23-26, 2018 in Orlando, Florida.
    • Nabanita Kundu, Laurence Asico, Cleyton C Domingues, Neeki Ahmadi, Pedro Jose, Sabyasachi Sen: Apoptosis resistant modified endothelial progenitor cell (EPC) transplantation improves diabetic kidney disease (DKD) at 54th Annual Meeting of The European Association for The Study of Diabetes, October 1-4 2018, Berlin, Germany
Locations